retatrutide clinical trials spain Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes Seeking Differentiation Through a Triple
Pay in 4 interest-free payments of $7.02 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24

























